Co-encapsulation of curcumin and tamoxifen in lipid-chitosan hybrid nanoparticles for cancer therapy. (29th July 2022)

• Record Type: Journal Article
• Authors: Alhajamee, Maitham; Marai, Khadeeja; Al Abbas, Sameer Mohammed Naser; Homayouni Tabrizi, Masoud
• Is Part Of: Materials technology. Volume 37:Number 9(2022)
• Page Start: 1183
• Page End: 1194
• Publication Date: 2022-07-29
• Subjects: encapsulation -- Lipid-Chitosan Hybrid Nanoparticles -- curcumin -- cancer therapy; Materials -- Periodicals; Materials science -- Periodicals; Materials -- Technological innovations -- Periodicals; 620.1105
• DOI: 10.1080/10667857.2021.1926811
• Languages: English
• ISSNs: 1066-7857

Abstract

ABSTRACT: Background: Lipid-polymer hybrid nanoparticles (LPHNP) are used for drug delivery due to their high advantages over polymeric or lipid nanoparticles. Materials and methods: Tamoxifen-Curcumin-loaded-LPHNPs (Tmx-Cu-LPHNPs) were synthetized by the ionic gelation method, and after characterization and calculation of the encapsulation efficiency, its antioxidant power, anti-cancer and anti-metastatic effects were examined. Results: Tmx-Cu-LPHNPswith size of 232.12 nm, PDI: 0.22, ζ-p: 35.12 mV and encapsulation efficiencies92% and 74% for Cu and Tmx (respectively) inhibited cancer cells more strongly than normal cells.In addition, Tmx-Cu-LPHNPsinhibited ABTS (IC50: 998.125 μg/ml), DPPH (IC50:164.87 μg/ml) free radicals as well as reducing iron ions.Up regulation of P53 and Caspase-9, flow cytometry and AO/PI staining demonstrated proapoptotic effects of Tmx-Cu-LPHNPs. Suppression of metastasis in cancer cells confirmed by scratch assay and decreased expression of metalloproteinase (MMP-2, 9) genes. Conclusion: Tmx-Cu-LPHNPs can be a promising factor in the treatment of cancer with appropriate therapeutic effects.